CompletedPhase 3NCT01295710

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Studying Rare disorder potentially indicated for transplant or complication after transplantation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Neovii Biotech
Principal Investigator
Anne Kuan
Neovii Biotech
Intervention
US-ATG-F(biological)
Enrollment
260 enrolled
Eligibility
18-65 years · All sexes
Timeline
20112015

Study locations (28)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01295710 on ClinicalTrials.gov

Other trials for Rare disorder potentially indicated for transplant or complication after transplantation

Additional recruiting or active studies for the same condition.

See all trials for Rare disorder potentially indicated for transplant or complication after transplantation

← Back to all trials